贞芪扶正胶囊与乙肝疫苗联用终止乙肝病毒低水平复制的临床研究

The Use of the Extracts of Ligustrum Lucidum Ait and Hedysarum Polybotrys H. M Combined with the Vaccine of Hepatitis B (EV Therapy) in Stopping Low Level Replication of HBV

目的:观察贞芪扶正胶囊与乙肝疫苗联用(EV治疗)对HBV不同复制水平的影响。方法:中～高水平复制者19例(A组)及低水平复制者26例(B组)给予EV治疗,另外低水平复制者19例(C组)作空白对照。以PCR及ELISA定量检测评价疗效。结果:A组5.26％病毒复制终止,HBsAg明显下降(P<0.01),35.71％HBeAg转阴。B组73.07％病毒复制终止,HBsAg下降非常显著(P<0.01),87.50％HBeAg转阴。C组5.26％病毒复制终止,而HBeAN、HBV-DNA阳性率有所升高,但统计学差异不明显(P>0.05)。组间比较B组明显优于A组和c组(P<0.01)。结论:EV治疗能抑制HBV的复制与表达,可使73.07％的低水平复制者近期获愈。

Objective: To evaluate the effects of the extracts of Ligustrum Lucidum Ait and Hedysarum Polybotrys H. M combined with the vaccine of hepatitis B (EV therapy) on low, middle-high level replication of HBV. Methods: Nineteen patients with middle-high level replication of HBV (group A) and 26 patients with low level replication (group B) were treated with EV, and 19 patients were in control group (group C). The therapeutic effects were evaluated with PCR and ELISA. Results: The replication and expression of HBV were stopped in 5.26% in group A, HbsAg significantly decreased (P<0.01), and 35.71% of HBeAg turned to negative. The replication and expression of HBV were stopped in 73.07% in group B, HbsAg significantly decreased ( P < 0.01) , and 87.50 % of HBeAg turned to negative. The replication and expression of HBV were stopped in 5.26% in group C. The effect of stopping the replication and expression of HBV in group B was better than that in group A and C (P<0.005). Conclusion: EV therapy certainly inhibits the replication and expression of HBV. It can make 73.07% cases with how level replication rehabilitate.